Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
Relief Therapeutics Holding SA (OTCQB: RLFTF), historically known as Relief Therapeutics, regularly issues news updates covering its biopharmaceutical pipeline, corporate milestones, and, more recently, its transformation into MindMaze Therapeutics Holding SA through a business combination with NeuroX Group SA. Company press releases describe a focus on rare dermatological, metabolic, and respiratory diseases, along with digital neurotherapeutics and an AI-powered brain health platform following the combination.
News items for RLFTF include clinical and regulatory developments such as FDA designations and meeting outcomes for RLF-TD011 in epidermolysis bullosa, and pivotal bioequivalence study results for RLF-OD032, a liquid sapropterin formulation for phenylketonuria. Investors and observers can also find updates on corporate governance events like annual general meetings, half-year and annual report publications, and shareholder approvals for strategic transactions.
Coverage further extends to transaction-related announcements, including the proposed and completed business combination with NeuroX, details on share exchanges, and the renaming of the company to MindMaze Therapeutics Holding SA. Subsequent communications describe the combined company’s activities in digital neurorehabilitation and neurological care, while noting that it continues to manage Relief’s preexisting biopharmaceutical assets.
By following RLFTF news, readers can track the evolution of Relief’s rare disease programs, its regulatory interactions, and the integration of its portfolio into the broader MindMaze Therapeutics platform. This news stream provides context on how the company positions its therapies and digital technologies within the rare disease and neurology landscapes.
Relief Therapeutics Holding SA has announced its Annual General Meeting (AGM) scheduled for May 31, 2022, which will be held without shareholder presence due to COVID-19. The Board recommends approval of key items including the Annual Report for 2021, carrying forward a loss of CHF 29,553,450, increasing authorized share capital to CHF 22 million, and approving compensation for the Board and Executive Committee totaling CHF 7.5 million. The meeting will also include re-elections for Board members and auditors.
Relief Therapeutics announced that its subsidiary, APR Applied Pharma Research, received a Notice of Allowance for Patent Application No. 15/303,121 from the U.S. Patent and Trademark Office. This patent covers PKU GOLIKE(R) formulations, enhancing dietary management for patients with phenylketonuria (PKU). The patent, valid until at least September 27, 2036, strengthens Relief's intellectual property and supports plans for a U.S. launch of PKU GOLIKE(R) in mid-2022, pending approval. The formulation is designed to mimic natural protein absorption while masking unpleasant flavors.
Relief Therapeutics announces the appointment of Drew Cronin-Fine as Executive Director, Head of U.S. Marketing, effective May 3, 2022. This strategic hire aims to bolster the U.S. commercial team ahead of the anticipated product rollouts for PKU GOLIKE and ACER-001, with a PDUFA date set for June 5, 2022. Cronin-Fine brings extensive experience from her previous roles at Intercept Pharmaceuticals and Cubist Pharmaceuticals, focusing on rare diseases and digital marketing strategies. This move is expected to enhance Relief's capabilities in the evolving rare disease market.
Relief Therapeutics announced that its partner, NRx Pharmaceuticals, has filed for Breakthrough Therapy Designation with the FDA for aviptadil in patients with Critical COVID-19 who were also treated with remdesivir. The request is based on a post-hoc analysis of around 750 patients and aims to address ongoing respiratory failure. Relief's ongoing collaborations also include a licensing agreement with Acer Therapeutics for another treatment. The PDUFA date for Acer's new drug application is set for June 5, 2022.
Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) presented data on ACER-001 at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting held from April 10-13, 2022. The studies demonstrated that taste-masked sodium phenylbutyrate (ACER-001) is bioequivalent to BUPHENYL® under both fasting and fed conditions, with similar safety profiles. The FDA's PDUFA date for ACER-001 is set for June 5, 2022, with potential benefits for patients with urea cycle disorders (UCDs). The findings highlight ACER-001 as a promising alternative therapy.
RELIEF THERAPEUTICS Holding SA announced that the Swiss Patent Office has granted a patent for Vasoactive Intestinal Peptide (VIP) for treating drug-induced pneumonitis, enhancing the intellectual property for RLF-100 (aviptadil) until at least 2039. This patent covers treatment for checkpoint inhibitor-related pneumonitis and methotrexate-induced pneumonitis. Clinical studies, including the NIH-sponsored ACTIVE-3b/TESICO study, are ongoing. Aviptadil's inhalation method shows promising results, offering rapid and targeted treatment, which can improve patient outcomes significantly.
Relief Therapeutics Holding SA announced that the I-SPY COVID Trial involving its product aviptadil has been halted due to a lack of clinical benefit in critically ill COVID-19 patients. The Phase 2 trial, sponsored by Quantum Leap Healthcare Collaborative, aimed to evaluate potential agents that could improve recovery times. Relief's pipeline includes RLF-100 and a collaboration with Acer Therapeutics for ACER-001, with a new drug application accepted by the FDA. The future of aviptadil’s approval remains uncertain amid ongoing litigation.
Relief Therapeutics reported full-year 2021 results with a net loss of CHF 34.7 million, up from CHF 7.8 million in 2020. The company generated CHF 3.3 million in revenue from marketed products following the acquisition of APR Applied Pharma Research. Relief is positioned for potential growth with plans for U.S. commercialization of ACER-001, pending FDA approval by June 5, 2022. The company ended 2021 with a cash position of CHF 44.8 million, forecasting a cash runway into 2023. Notable acquisitions and product developments are set to enhance its commercial infrastructure.
Relief Therapeutics' subsidiary, APR Applied Pharma Research, published promising in vivo data in the International Journal of Molecular Sciences. The study indicates that its PhysiomimicTM technology may provide prolonged release of amino acids (AAs), beneficial for managing phenylketonuria (PKU). Results show improved nitrogen balance, muscle mass, and strength in animal models. CEO Paolo Galfetti emphasized the potential of PKU GOLIKE(R), a product utilizing this technology, to mimic natural protein absorption. Relief aims for U.S. market entry of PKU GOLIKE(R) in 2022 while pursuing further clinical evidence.
Relief Therapeutics announced that it has received a trademark registration for RLF-100 from the USPTO. This certification is significant as it strengthens the company’s intellectual property position for RLF-100, a drug in late-stage development targeting respiratory issues related to COVID-19 and other conditions. RLF-100 is a synthetic form of Vasoactive Intestinal Peptide with a proven history of safe use in several trials. The company aims to leverage this trademark to enhance its market position as it navigates ongoing clinical testing.